From the clinic to the capital markets, here is Psychedelic Invest's roundup of the key headlines for the week of July 13–19, 2026.
U.S. FDA (regulatory): FDA finalizes psychedelic clinical trial guidance and schedules September public hearing
The FDA released final guidance on considerations for psychedelic clinical investigations, finalizing its 2023 draft and offering sponsors more flexibility on modeling abuse potential and measuring efficacy while addressing functional-unblinding challenges. The agency also scheduled a September 14, 2026 public hearing on the therapeutic use of psychedelics in supervised settings. Analysts characterized the receptive tone as reducing regulatory risk for developers such as Compass Pathways, AtaiBeckley, Cybin/Helus and GH Research.
Source: techtimes.com
Eli Lilly and Company / AtaiBeckley Inc. (LLY): Bloomberg reports Eli Lilly nearing deal to acquire AtaiBeckley
Bloomberg reported that Eli Lilly was nearing an agreement to acquire psychedelic drugmaker AtaiBeckley, sending AtaiBeckley shares higher on the prospect of a Big Pharma entry into the sector. The report set up the following day's formal announcement. It signaled growing large-cap pharmaceutical conviction in psychedelic therapies for depression.
Source: bloomberg.com
Eli Lilly and Company / AtaiBeckley Inc. (LLY): Eli Lilly to acquire AtaiBeckley for about $2.8 billion, up to $3.8 billion with milestones
Eli Lilly and AtaiBeckley announced a definitive agreement for Lilly to acquire AtaiBeckley at $6.75 per share in cash, roughly $2.8 billion upfront and up to $3.8 billion including milestones, about a 40% premium to the recent VWAP. The lead asset is BPL-003 (mebufotenin benzoate), an intranasal synthetic 5-MeO-DMT for treatment-resistant depression heading into Phase 3. Expected to close in Q3 2026 subject to shareholder and regulatory approval, the deal marks a landmark Big Pharma acquisition in psychedelics and a validating exit for the sector.
Source: prnewswire.com
That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.